ERAS Erasca, Inc.

company

SEC Filings & Insider Trading Activity 2026

Business Overview

• • Core business: Precision oncology company focused exclusively on discovering and developing therapies targeting RAS/MAPK pathway-driven cancers
• • New emphasis: Clinical-stage programs ERAS-0015 (pan-RAS molecular glue) and ERAS-4001 (pan-KRAS inhibitor) initiated INDs May 2025, first clinical data expected H1/H2 2026

Risk Factors

• • Regulatory risk from compliance with EU Clinical Trials Regulation (CTR) effective January 31, 2025 impacting multi-center trial approvals
• • Geopolitical risk from potential delays and cost increases due to evolving U.S. tariff and import/export regulations affecting operations

Management Discussion & Analysis

• • No revenue generated; net loss $124.5M in 2025 vs $161.7M in 2024, improving by $37.1M
• • Operating expenses down to $140.9M in 2025 from $179.6M in 2024; R&D expense 22% lower at $92.9M vs $115.4M

Risk Factors

• • No new or changed risk factors reported versus 2024 10-K
• • Clinical trial delays and regulatory approvals remain key operational risks impacting near-term milestones

What are the latest ERAS SEC filings in 2026?

Erasca, Inc. (ERAS) has filed a 10-K annual report on March 12, 2026, a 10-Q quarterly report on November 12, 2025, an 8-K current report on April 27, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.

When did ERAS file its most recent 10-K annual report?

Erasca, Inc. (ERAS) filed its most recent 10-K annual report on March 12, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.

How do I view ERAS 10-Q quarterly reports?

Erasca, Inc. (ERAS)'s most recent 10-Q quarterly report was filed on November 12, 2025. SignalX displays every ERAS 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.

What 8-K current reports has ERAS filed recently?

Erasca, Inc. (ERAS)'s most recent 8-K was filed on April 27, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.

Where can I find ERAS insider trading activity (Form 4)?

SignalX aggregates every ERAS Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.

How often does ERAS file with the SEC?

Erasca, Inc. (ERAS) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new ERAS filing with AI-powered analysis.

What is the difference between 10-K, 10-Q, and 8-K SEC filings?

A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs — such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Erasca, Inc. (ERAS).

What is ERAS's SEC CIK number?

Erasca, Inc. (ERAS)'s SEC CIK (Central Index Key) number is 1761918. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1761918 to look up all ERAS filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.

Where can I find ERAS return on equity (ROE) and financial data?

SignalX extracts XBRL financial data from Erasca, Inc. (ERAS) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.